clinical evidence bpc-157 safety BPC-157: Miracle Healing Peptide or Hidden Danger? FDA's Review Of Peptides Signals

A smaller but growing body of preclinical literature investigates BPC-157 within neurological and braingut communication models

Accessed June 23, 2025.

The FDAs approval was based on results from the Phase III CheckMate901 trial, where the combo regimen demonstrated a statistically significant improvement in overall survival and progression-free survival compared to cisplatin-gemcitabine alone, BMS reported

However, these cardiovascular applications require particularly careful consideration given the potential risks associated with promoting angiogenesis in patients who may have undiagnosed malignancies or other conditions where angiogenesis promotion could be detrimental